Boston Imaging, the U.S. headquarters of Samsung’s digital radiography and ultrasound business, inked the deal. Lunit offers AI technology for cancer diagnostics and therapeutics. Together, they aim to enable faster and more accurate chest screenings for timely interventions with improved patient outcomes.
The companies plan to combine Lunit’s Insight CXR and Insight CXR Triage with Samsung’s computer-aided detection (CAD) AI. Lunit’s chest X-ray analysis technology and FDA-cleared AI triage solution enable the CAD AI to help radiologists manage patient exams by prioritizing those with suspected abnormalities.
Samsung Head of Digital Radiography, Eric Sumner, said chest X-rays are the “most requested exam in radiography.”
“By partnering with Lunit, our Samsung digital radiology products will now have computer-assisted triage and notification software that analyzes adult chest X-ray images for the presence of suspected pleural effusion or pneumothorax,” Sumner said. “Patients with suspected findings will move to the top of the radiologist queue, allowing patients to be diagnosed more quickly. This will provide critical information to radiologists as they triage urgent cases.”
The companies now offer the Lunit AI solution on Samsung digital radiology products as of the first quarter of 2024. As part of the collaboration, Samsung plans to continue expanding the validation of the AI solution. The company wants to help detect the 10 most common abnormalities in chest X-rays, including nodules, pneumothorax, atelectasis, cardiomegaly, calcification, consolidation, pleural effusion, pneumoperitoneum, mediastinal widening, fibrosis, and support tuberculosis screening.
Samsung plans to offer the upgraded systems to the North American and European markets. It also plans to expand to the Middle East, South America and Southeast Asia.
